| 2025 | Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy | NEW ENGLAND JOURNAL OF MEDICINE |
| 2025 | Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitor | Results in Chemistry |
| 2025 | Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer
| LUNG CANCER |
| 2025 | Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer
| FUTURE ONCOLOGY |
| 2025 | Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2025 | Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
| LUNG CANCER |
| 2025 | ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib | JCO PRECISION ONCOLOGY |
| 2025 | Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy | LUNG CANCER |
| 2025 | Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA
| FUTURE ONCOLOGY |
| 2025 | Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
| JOURNAL OF CLINICAL ONCOLOGY |
| 2025 | Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib
| ANNALS OF ONCOLOGY |
| 2025 | Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2025 | Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study | LUNG CANCER |
| 2025 | A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial | LUNG CANCER |
| 2025 | Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
| MOLECULAR CANCER THERAPEUTICS |
| 2025 | Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC
| CANCERS |
| 2025 | The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC
| CELL REPORTS MEDICINE |
| 2025 | Harnessing the Potential of FAP-IL12mut TMEkine for Targeted and Enhanced Antitumor Responses
| MOLECULAR CANCER THERAPEUTICS |
| 2025 | FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)
| LUNG CANCER |
| 2025 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
| CANCER RESEARCH AND TREATMENT |
| 2024 | Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
| FUTURE ONCOLOGY |
| 2024 | Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study
| FUTURE ONCOLOGY |
| 2024 | NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
| CANCER DISCOVERY |
| 2024 | ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial | CLINICAL CANCER RESEARCH |
| 2024 | Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3 | JOURNAL OF THORACIC ONCOLOGY |
| 2024 | Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma
| ESMO OPEN |
| 2024 | ASO Visual Abstract: Left Upper Division Segmentectomy Compared with Lobectomy for Lung Expansion and Bronchus Tortuosity | ANNALS OF SURGICAL ONCOLOGY |
| 2024 | Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study
| BMC MEDICINE |
| 2024 | Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2024 | Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
| ONCOLOGIST |
| 2024 | Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation | LUNG CANCER |
| 2024 | Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
| 2024 | Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
| Lung Cancer : targets and therapy |
| 2024 | BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2024 | PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
| FUTURE ONCOLOGY |
| 2024 | Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA | ANNALS OF ONCOLOGY |
| 2024 | Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2024 | D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
| CANCER DISCOVERY |
| 2024 | Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities | LUNG CANCER |
| 2024 | Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer | CLINICAL CANCER RESEARCH |
| 2024 | A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study | Cancer Treatment and Research Communications |
| 2024 | Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
| CANCER RESEARCH COMMUNICATIONS |
| 2024 | Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
| BMC CANCER |
| 2024 | Novel allosteric glutaminase inhibitors with macrocyclic structure activity relationship analysis (part 2) | BULLETIN OF THE KOREAN CHEMICAL SOCIETY |
| 2024 | ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC) | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)
| ONCOIMMUNOLOGY |
| 2024 | Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
http://orcid.org/0000-0002-5562-270X
(7401747804)
